Nicotinamide to prevent skin cancer after organ transplant
Treatments studied
Part of Cancer clinical trials.
This trial tests nicotinamide (a vitamin-like medicine) to help prevent new keratinocyte skin cancers in people who have had a kidney, liver, heart, or lung transplant. It may lower the chance of developing new skin tumors while you continue your usual transplant anti-rejection medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a kidney, liver, heart, or lung transplant at least 2 years ago
- You have had at least one prior skin cancer of the keratinocyte type (or squamous cell carcinoma in situ), confirmed by biopsy
- You take anti-rejection medicine that includes tacrolimus or cyclosporine
- You can come to follow-up visits during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a daily cream with 5% niacinamide (a form of vitamin B3) can help prevent skin cancer in people who have had an organ transplant. You will apply the cream to your skin and also use sunscreen every day.
This early trial tests whether adding vitamin A and niacinamide (a form of vitamin B3) can help people with a history of certain skin cancers reduce new disease. It is designed for adults with specific prior skin cancer or skin lesion treatment patterns.
This Phase 2 trial tests whether nicotinamide (a form of vitamin B3) can help people with chronic lymphocytic leukemia (CLL) who have had non-melanoma skin cancers in the past 5 years. The study looks at how well new skin cancers can be prevented or reduced.
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
This trial tests whether nicotinamide riboside can help prevent heart problems caused by a common breast-cancer chemotherapy (anthracyclines). If you’re eligible, you’ll be followed to see how your heart is doing during treatment.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
Hear when a new Non-Melanoma Skin Cancer (NMSC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.